Related Experiment Video
Updated: Oct 4, 2025
10:04
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
13.2K
"Off-the-shelf" immunotherapies for multiple myeloma
Turab Mohammed1, Sham Mailankody2
1Department of Medicine, University of Connecticut School of Medicine, Farmington, CT.
Seminars in Oncology
|February 6, 2022
Summary
New multiple myeloma (MM) therapies, including antibody-drug conjugates and bispecific antibodies, show promise for durable remission in patients resistant to standard treatments.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Multiple myeloma (MM) survival has improved, but the disease remains incurable.
- A subset of MM patients require novel therapies after progressing on standard treatments.
- B-Cell Maturation Antigen (BCMA) is a key target in MM pathogenesis.
Purpose of the Study:
- To review emerging data on "off-the-shelf" immunotherapeutic approaches for MM.
- To highlight novel strategies beyond autologous CAR-T cell therapy.
- To discuss feasibility, safety, and efficacy of new MM treatments.
Main Methods:
- Review of ongoing clinical trials for novel MM therapies.
- Analysis of data on antibody-drug conjugates, bispecific antibodies, and allogeneic cellular therapies.
- Evaluation of emerging immunotherapeutic strategies targeting BCMA.
Main Results:
- "Off-the-shelf" approaches demonstrate feasibility and acceptable safety.
- Preliminary efficacy data for novel therapies are promising.
- Autologous CAR-T cell therapy shows high efficacy but has limitations.
Conclusions:
- Novel "off-the-shelf" immunotherapies offer new hope for MM patients.
- Future research should focus on comparative effectiveness and combination strategies.
- Ensuring global access and affordability of these advanced therapies is crucial.
Keywords:
Allogeneic CAR-TAntibody-drug conjugateBispecific antibodyCAR-NK cell therapyChimeric antigen receptor-T cell therapyMultiple myelomaMore Related Videos
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.7K
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
6.9K
Related Concept Videos
01:27Tumor Immunotherapy
711
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
711
02:57Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
01:31Hybridoma Technology
15.6K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.6K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:30Cancer Vaccines
544
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
544
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K